Advertisement

Journal of Inherited Metabolic Disease

, Volume 37, Issue 1, pp 39–42 | Cite as

Maternal Phenylketonuria International Collaborative Study revisited: evaluation of maternal nutritional risk factors besides phenylalanine for fetal congenital heart defects

  • Shoji Yano
  • Kathryn Moseley
  • Teodoro Bottiglieri
  • Erland Arning
  • Colleen Azen
Original Article

Abstract

Maternal phenylketonuria (MPKU) is known to affect fetal outcome, often being associated with microcephaly and congenital heart defects (CHD) if the maternal diet is not appropriately managed. We hypothesized that other nutrients aside from phenylalanine (Phe) may have significant effects on fetal outcome in MPKU pregnancies. The 416 pregnancies that resulted in live births reported in the Maternal PKU Collaborative Study (MPKUCS) were grouped according to whether or not the offspring were diagnosed with CHD. The groups were compared on first-trimester values of maternal data, including weight gain, plasma amino acids, protein and Phe intake, and red blood cell (RBC) folate. Patients were also grouped by first-trimester average blood Phe (≤910 μmol/L and >910 μmol/L) and then divided by total natural protein and medical food intake. The CHD group of 28 offspring had significantly higher blood Phe and lower proline, valine, methionine, isoleucine, leucine, lysine, arginine, and RBC folate. A significantly higher risk for CHD was found in the groups with lower natural protein and medical food intake, regardless of blood Phe levels. Insufficient natural protein and medical food product intake appears to be a risk factor for CHD independent of first-trimester plasma Phe levels. Low RBC folate and plasma methionine levels in the CHD group may suggest involvement of global DNA hypomethylation.

Keywords

Congenital Heart Defect Plasma Amino Acid Congenital Heart Defect Large Neutral Amino Acid Plasma Methionine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgments

Analysis for this project was supported in part by NIH NCRR SC-CTSI Grant Number UL1 RR031986. We thank our mentor, Dr. Richard Koch, for his work on the MPKUCS. We also appreciate Ms. Carolina Coleman for her dedication to and compassion for this project.

Conflict of interest

None.

References

  1. Blau N, van Spronsen FJV, Levy HL (2010) Phenylketonuria. Lancet 376:1417–1427PubMedCrossRefGoogle Scholar
  2. Campbell WA, Sah DE, Medina MM, Albina JE, Coleman WB, Thompson NL (2000) TA1/LAT-1/CD98 light chain and system L activity, but not 4F2/CD98 heavy chain, respond to arginine availability in rat hepatic cells. Loss of response in tumor cells. J Biol Chem 275(8):5347–5354PubMedCrossRefGoogle Scholar
  3. Chowdhury S, Cleves MA, MacLeod SL, James SJ, Zhao W, Hobbs CA (2011) Maternal DNA hypomethylation and congenital heart defects. Birth Defects Res A 91:69–76CrossRefGoogle Scholar
  4. Chrostowski MK, McGonnigal BG, Stabila JP, Padbury JF (2009) LAT-1 expression in pre- and post-implantation embryos and placenta. Placenta 30:270–276PubMedCentralPubMedCrossRefGoogle Scholar
  5. Cooney CA, Dave AA, Wolff GL (2001) Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. J Nutr 132:2393S–2400SGoogle Scholar
  6. Feng Q, Song W, Lu X et al (2002) Development of heart failure and congenital septal defects in mice lacking endothelial nitric oxide synthase. Circulation 106:873–879PubMedCrossRefGoogle Scholar
  7. Inoue-Choi M, Nelson HH, Robien K et al (2003) One-carbon metabolism nutrient status and plasma S-adenosylmethionine concentrations in middle-aged and older Chinese in Singapore. Int J Mol Epidemiol Genet 3(2):160–173Google Scholar
  8. Koch R, Azen C, Friedman E et al (2003) Research design, organization, and sample characteristics of the maternal PKU collaborative study. Pediatrics 112:1519–1522PubMedGoogle Scholar
  9. Pietz J, Kreis R, Rupp A et al (1999) Large neutral amino acids block phenylalaninetransport into brain tissue in patients with phenylketonuria. J Clin Invest 103:1169–1178PubMedCentralPubMedCrossRefGoogle Scholar
  10. Prick BW, Hop WCJ, Duvekot JJ (2012) Maternal phenylketonuria and hyperphenylalaninemia in pregnancy: pregnancy complications and neonatal sequelae in untreated and treated pregnancies. Am J Clin Nutr. doi: 10.3945/ajcn110.0009456 PubMedGoogle Scholar
  11. Rouse B, Azen C (2004) Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: the importance of strict dietary control preconception and throughout pregnancy. J Pediatr 144:235–239PubMedCrossRefGoogle Scholar
  12. Surtees R, Blau N (2000) The neurochemistry of phenylketonuria. Eur J Pediatr 159(Suppl 2):S109–S113PubMedCrossRefGoogle Scholar
  13. Teissier R, Nowak E, Assoun M et al (2012) Maternal phenylketonuria: low phenylalaninemia might increase the risk of intrauterine growth retardation. J Inherit Metab Dis. doi: 10.1007/s10545-012-9491-0 PubMedGoogle Scholar
  14. Van Direl LMJW, de Jonge R, Helbing WA et al (2008) Maternal global methylation status and risk of congenital heart diseases. Obstet Gynecol 112(2):277–283CrossRefGoogle Scholar
  15. Vogel KR, Arning E, Wasek BL, Bottiglieri T, Gibson KM (2012) Non-physiological amino acid (NPAA) therapy targeting brain phenylalanine reduction: pilot studies in PAH (ENU2) mice. J Inherit Metab Dis [Epub ahead of print].Google Scholar
  16. Weetch E, Macdonald A (2006) The determination of phenylalanine content of foods suitable for phenylketonuria. J Hum Nutr Diet 19(3):229–236PubMedCrossRefGoogle Scholar

Copyright information

© SSIEM and Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Shoji Yano
    • 1
  • Kathryn Moseley
    • 1
  • Teodoro Bottiglieri
    • 2
  • Erland Arning
    • 2
  • Colleen Azen
    • 3
  1. 1.Genetics Division, Department of Pediatrics, LAC + USC Medical Center, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA
  2. 2.Institute of Metabolic Disease, Baylor Research InstituteDallasUSA
  3. 3.Clinical and Translational Science Institute, Children’s Hospital Los Angeles, Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA

Personalised recommendations